Advances in mesenchymal stem cell-mediated gene therapy for cancer
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Mesenchymal stem cells have a natural tropism for tumours and their metastases, and are also considered immunoprivileged. This remarkable combination of properties has formed the basis for many studies investigating their potential as tumour-specific delivery vehicles for suicide genes, oncolytic viruses and secreted therapeutic proteins. The aim of the present review is to discuss the range of approaches that have been used to exploit the tumour-homing capacity of mesenchymal stem cells for gene delivery, and to highlight advances required to realize the full potential of this promising approach.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tumors: Wounds That Do Not Heal
Flier, J. S., Underhill, L. H., & Dvorak, H. F. (1986) · New England Journal of Medicine · doi:10.1056/nejm198612253152606 · Cited by 4,391 · cited 1×
“Th e tumour microenvironment is considered a site of chronic infl ammation [31].”
BackgroundMesenchymal stem cells within tumour stroma promote breast cancer metastasis
Karnoub, A. E., Dash, A. B., Vo, A. P., Sullivan, A., Brooks, M. W., Bell, G. W., Richardson, A. L., Polyak, K., Tubo, R., & Weinberg, R. A. (2007) · Nature · doi:10.1038/nature06188 · Cited by 3,206
Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals
Djouad, F., Plence, P., Bony, C., Tropel, P., Apparailly, F., Sany, J., Noël, D., & Jorgensen, C. (2003) · Blood · doi:10.1182/blood-2003-04-1193 · Cited by 1,166 · cited 2×
“Additionally, as previously mentioned, the immunosuppressive qualities of MSCs may support tumour development and progression through protection of cancer cells from immune surveillance [27].”
BackgroundCarcinoma-associated fibroblast-like differentiation of human mesenchymal stem cells
Mishra, P. J., Mishra, P. J., Humeniuk, R., Medina, D. J., Alexe, G., Mesirov, J. P., Ganesan, S., Glod, J. W., & Banerjee, D. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0943 · Cited by 912 · cited 2×
“Th ere is also evidence that MSCs may serve as precursors for carcinoma-associated fi broblasts and/or pericytes, playing a potentially important role in tumour angiogenesis through diff erentiation and the release of proangiogenic factors [67-69, 71-76 ].”
BackgroundSpaeth, E. L., Dembinski, J. L., Sasser, A. K., Watson, K., Klopp, A., Hall, B., Andreeff, M., & Marini, F. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004992 · Cited by 807
Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma
Khakoo, A. Y., Pati, S., Anderson, S. A., Reid, W., Elshal, M. F., Rovira, I. I., Nguyen, A. T., Malide, D., Combs, C. A., Hall, G., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20051921 · Cited by 747
Honczarenko, M., Le, Y., Swierkowski, M., Ghiran, I., Glodek, A. M., & Silberstein, L. E. (2006) · Stem Cells · doi:10.1634/stemcells.2005-0319 · Cited by 722
Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model
Nakamura, K., Ito, Y., Kawano, Y., Kurozumi, K., Kobune, M., Tsuda, H., Bizen, A., Honmou, O., Niitsu, Y., & Hamada, H. (2004) · Gene Therapy · doi:10.1038/sj.gt.3302276 · Cited by 597
Adipose Tissue–Derived Human Mesenchymal Stem Cells Mediated Prodrug Cancer Gene Therapy
Kucerova, L., Altanerova, V., Matuskova, M., Tyciakova, S., & Altaner, C. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4024 · Cited by 431 · cited 3×
“Recent studies have incorporated the use of lentivirus-mediated transduction [13,16,48,53], retrovirus-mediated transduction [10,19,20,22] or plasmid-mediated transduc tion [21]; however, the majority remain adenovirus based [5-8,11,14,15,17,18,23-25,54,55].”
BackgroundMethodMesenchymal Stem Cell Delivery of TRAIL Can Eliminate Metastatic Cancer
Loebinger, M. R., Eddaoudi, A., Davies, D., & Janes, S. M. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4698 · Cited by 417 · cited 13×
“Like most healthy tissues, MSCs are resistant to TRAIL-induced apoptosis due to their very low levels of active receptors [17].”
BackgroundMethodInfluential
Cited by
Russell, S. J., Peng, K.-W., & Bell, J. C. (2012) · Nature Biotechnology · doi:10.1038/nbt.2287 · Cited by 1,428
Klopp, A. H., Gupta, A., Spaeth, E., Andreeff, M., & Marini, F. (2011) · Stem Cells · doi:10.1002/stem.559 · Cited by 562
Tumour-associated mesenchymal stem/stromal cells: emerging therapeutic targets
Shi, Y., Du, L., Lin, L., & Wang, Y. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.193 · Cited by 460
Abumaree, M. H., Al Jumah, M. A., Kalionis, B., Jawdat, D., Al Khaldi, A., Abomaray, F. M., Fatani, A. S., Chamley, L. W., & Knawy, B. A. (2013) · Stem Cell Reviews and Reports · doi:10.1007/s12015-013-9455-2 · Cited by 354
Bronckaers, A., Hilkens, P., Martens, W., Gervois, P., Ratajczak, J., Struys, T., & Lambrichts, I. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.02.013 · Cited by 354
Babajani, A., Soltani, P., Jamshidi, E., Farjoo, M. H., & Niknejad, H. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.00748 · Cited by 99
Rossignoli, F., Spano, C., Grisendi, G., Foppiani, E. M., Golinelli, G., Mastrolia, I., Bestagno, M., Candini, O., Petrachi, T., Recchia, A., et al. (2019) · Theranostics · doi:10.7150/thno.27576 · Cited by 55
Yang, L., Zhang, Y., Cheng, L., Yue, D., Ma, J., Zhao, D., Hou, X., Xiang, R., & Cheng, P. (2016) · Human Gene Therapy · doi:10.1089/hum.2015.135 · Cited by 39
“15 Here, we found that MSC-mediated Ad-PEDF delivery reduces production of adenoviral neutralizing antibodies and prolongs PEDF expression in vivo (Fig.”
InfluentialLEE, S.-W., JEON, T. J., & BISWAL, S. (2015) · Oncology Reports · doi:10.3892/or.2015.3711 · Cited by 10
Metadata
- Authors
- Dwyer, R. M., Khan, S., Barry, F. P., O'Brien, T., & Kerin, M. J.
- Venue
- Stem Cell Research & Therapy
- Published
- 2010-08-09
- Volume
- 1
- Issue
- 3
- Pages
- 25-25
- ISSN
- 1757-6512 (ISSN-L)
- OpenAlex
- W2108776158
- Cited by
- 115
- References
- 20
- FWCI
- 4.92
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.